Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
There is also a growing interest in whole generation sequencing (WGS)
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Subscribe To Our Newsletter & Stay Updated